Cephalosporin Market Expert Reviews & Analysis Along With Study Report 2023

Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to treat bacterial infections. The major factors contributing to the growth of the market include increase in incidence of population suffering from pneumonia, tonsillitis, bronchitis, and gonorrhea. In addition, increase in R&D activities to develop highly efficient & safe drugs and upsurge in use of combination therapies further boost the market growth. However, side effects associated with cephalosporin and development of drug-resistant bacterial strains restrain the market growth.

Get Access to TOC / Sample Report @ https://www.alliedmarketresearch.com/request-sample/3510?utm_source=openpr_ss

The global cephalosporin market was valued at $3,136 million in 2016, and is projected to reach $4,980 million by 2023, growing at a CAGR of 6.8% from 2017 to 2023. The third-generation cephalosporin segment held around one-third share of the total market in 2016.

Third-generation cephalosporin segment is expected to dominate the market throughout the analysis period, as these have a broader spectrum of activity. Fifth-generation cephalosporin is expected to register the highest CAGR of 7.6% during the forecast period.

Make a Purchase Enquiry of Report @ https://www.alliedmarketresearch.com/purchase-enquiry/3510?utm_source=openpr_ss

Market Players:

• Allergan Plc
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Lupin Limited
• Merck & Co.

KEY FINDINGS OF THE STUDY :

• Fifth-generation cephalosporin is projected to grow at a CAGR of 15.6% during the forecast period.

• Branded cephalosporin segment is expected to register the highest CAGR of 14.4% during the analysis period.

• Injectable cephalosporin is accounted for more than two-fifths share of the global cephalosporin market in 2016.

• France and Germany collectively contributed for around one-third share of the European cephalosporin market in 2016.

• Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific cephalosporin market in 2016.

Browse More Information of Report @ https://www.alliedmarketresearch.com/press-release/cephalosporin-market.html?utm_source=openpr_ss

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.